Deals in Depth: August 2011
Executive SummaryMerck is tasking Zymeworks' Azymetric platform for bi-specific cancer and autoimmune antibodies in a $187 million alliance. Par paid $410 million for generics company Anchen, while Baxter acquired additional medical delivery systems through its $380 million purchase of Baxa. With $334 million raised, device financing surpassed biopharma's $224 million in fundraising in August, thanks to large late-stage rounds from NeuroPace, Restoration Robotics and Entellus.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.